54001 Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks: Subgroup Analysis by Baseline Demographics and Disease Characteristics from the LIMMitless Trial
Journal of the American Academy of Dermatology(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要